FIELD: biotechnology.
SUBSTANCE: group of inventions relates to stable aqueous solutions containing an antibody to C5 in a high concentration and methods for the production of these solutions. The stable aqueous solution contains an antibody to C5 at a concentration of 100 mg/ml ± 5%, 50 mM ± 5% of a phosphate buffer, 5% ± 5% of sucrose. In another option, the solution also contains 0.05% ± 5% of polysorbate 80. The antibody to C5 contains a heavy chain with SEQ ID NO: 14 and a light chain with SEQ ID NO: 11. Methods for the treatment or prevention of disorders associated with C5 complement system, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic-uremic syndrome (aHUS), using these solutions, are also proposed. Therapeutic kits containing the specified solution and a means for administration of the solution to a patient who needs treatment are also presented.
EFFECT: invention provides a stable highly concentrated aqueous solution of an antibody to C5, which remains for at least 97% monomeric and preserves at least 90% of its C5-binding activity during storage at 2-8°C for at least six months.
27 cl, 53 dwg, 23 tbl, 3 ex
Title |
Year |
Author |
Number |
DOSES AND ADMINISTRATION OF ANTIBODIES AGAINST C5 FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) |
2020 |
- Pejton, Lori
- Miks, Kristian
- Pradkhan, Radzhendra
- Damokosh, Andryu
- Svenson, Yudzhin Skott
- Gao, Syan
|
RU2822664C2 |
GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS |
2014 |
- Dr. Wagner Thomas
- Carlsson Malin
- Staum Kaltoft Margit
|
RU2714919C2 |
ANTIBODIES AGAINST E-SELECTIN, COMPOSITIONS AND METHODS OF USE |
2021 |
- Apgar, Dzhejms Rizoner
- Bouli, Sheril Rubio
- Elvell, Dzhoann Elizabet-Ajriss
- Lin, Laura
- Narula, Dzhatin
- Parng, Chuenlej
- Pittman, Debra Denene
- Rakkhe, Svapnil
- Yuj, Chikhij Vinsent
|
RU2805176C1 |
PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF |
2019 |
- Yang, Jianjian
- Li, Hao
- Liu, Xun
- Jiang, Jiahua
|
RU2778572C1 |
COMPOSITION CONTAINING ANTIBODY AGAINST ABETA PROTOFIBRILS AND INHIBITOR OF BETA-SECRETASE BACE1 FOR TREATMENT OF ALZHEIMER'S DISEASE |
2017 |
- Satlin, Andrew
- Fukushima, Tatsuto
|
RU2786476C2 |
STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE |
2018 |
- De, Arnab
- Narasimkhan, Chakravarti Nachu
|
RU2820576C2 |
SELECTION OF PATIENTS WITH HEADACHE SUSCEPTIBLE TO ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE |
2018 |
|
RU2770066C2 |
PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS |
2023 |
- Shukurov Rakhim Rakhmankulyevich
- Reshetnik Elizaveta Vyacheslavovna
- Khamitov Ravil Avgatovich
- Shuster Aleksandr Mikhajlovich
|
RU2814280C1 |
PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION |
2019 |
- Tyan, Chenmin
- Li, Khao
- Lyu, Syun
|
RU2791683C2 |
COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY |
2019 |
- Antoshchuk, Valentin
- Desai, Priti, Dzh.
- Krishnamakhari, Jogita
- Sangani, Sakhil, S.
|
RU2822192C2 |